| Vaccine | Bivalent | Quadrivalent | Nonavalent |
| VPL | 16/18 | 6/11/16/18 | 6/11/16/18/31/33/45/52/58 |
| Adjuvant | ASO4 (detoxified form of lipopolysaccharide and aluminium hydroxide) | Aluminium hydroxide | Aluminium hydroxide |
| Indications | · Precancerous lesions of the cervix, vulva, vagina, anus · Cancer cervix, anus | · Precancerous lesions of the cervix, vulva, vagina, anus · Cancer cervix, anus · Anogenital warts | · Precancerous lesions of the cervix, vulva, vagina, anus · Cancer cervix, anus · Anogenital warts |
| Population and dosage | People 9 - 14 years old (inclusive): 2 doses; 0 and 6 months People 15 years or older: 3 doses; 0.1 and 6 months | People 9 - 13 years old (inclusive): two guidelines · 2 doses; 0 and 6 months · 3 doses; 0.2 and 6 months People 14 years and older: 3 doses; 0.2 and 6 months | People 9 - 14 years old (inclusive): two guidelines · 2 doses; 0 and 6 months · 3 doses; 0.2 and 6 months People 15 years or older: 3 doses; 0.2 and 6 months |
| Coverage | 70% cancer of the vulva, cervix, vagina, penis, anus, or opharynx | +90% genital warts | +20% cervical cancer |